<DOC>
	<DOCNO>NCT01984619</DOCNO>
	<brief_summary>To evaluate safety effectiveness iovera° device blunt tip cannula treatment forehead wrinkle .</brief_summary>
	<brief_title>Prospective Study Evaluating Treatment Hyperdynamic Forehead Wrinkles</brief_title>
	<detailed_description />
	<criteria>Male Females 1865 year age . Forehead wrinkle ( ) rating least 2 animation 5point Wrinkle Scale ( 5WS ) upon physical manipulation skin demonstrate reduction wrinkle severity . Subject least 2 point difference rest dynamic forehead wrinkle score use 5WS . Glabellar wrinkle score `` 1 '' high animation 5point Glabella Scale ( 5GS ) . Fitzpatrick Skin Type I , II , III , IV . Subject consent agree participate study procedure visit study 's duration . Subject good general health , free disease state , physical condition might impair evaluation forehead and/or glabellar wrinkle rating , Investigator 's opinion , expose subject unacceptable risk study participation . Subject clot disorder coagulopathy require use anticoagulant and/or antiplatelet therapy ( e.g. , warfarin , clopidigrel , etc . ) Subject use medication supplement affect clot cascade ( e.g. , aspirin , fish oil , etc . ) , nonsteroidal antiinflammatory drug ( NSAIDs , e.g. , ibuprofen naproxen ) within seven ( 7 ) day prior administration device . Subject prior surgery alters subcutaneous anatomy target treatment site . Subject undergone another surgical cosmetic procedure botulinum toxin injection level zygoma ( cheekbone ) within past six ( 6 ) month prior administration device . Subject rest wrinkle score `` 3 '' high 5WS . Subjects actively elevate forehead rest . Subject treat filler temple forehead area time interval specify prior start participation study . Subject following : 1 . Dermatochalasis &lt; 1mm lid margin look straight ahead . 2 . Excessive skin laxity . 3 . Asymmetry upper face . 4 . History facial nerve palsy . 5 . Eyebrow eyelid ptosis . 6 . History neuromuscular disorder . 7 . Chronic dry eye symptom . 8 . Allergy intolerance local anesthetic agent ( e.g. , Lidocaine ) . 9 . Use narcotic medication chronic pain condition . 10 . Any clinically significant , opinion Investigator , local skin condition ( e.g. , skin infection ) target treatment site may interfere safety concern . 11 . Any physical psychiatric condition Investigator 's opinion would prevent adequate study participation . 12 . Chronic medical condition Investigator 's opinion would affect study participation ( uncontrolled hypertension , diabetes , hepatitis , HIV , etc. ) . 13 . Diagnosis : Cryoglobinemia Paroxysmal cold hemoglobinuria Cold Uticaria Raynaud 's Disease Open and/or infect wound Existing neuromuscular disease 14 . Fitzpatrick Skin Type V IV 15 . Subject currently enrol investigational drug , biologic device study could affect safety effectiveness iovera° treatment . 16 . Subject know noncompliant unlikely comply requirement study protocol opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>